1. Scrip
  2. >>Therapy Areas
  3. >>Neurological

Novartis Excited About Iptacopan But Downcast After Huntington’s Blow

Branaplam Development Halted

 
• By Kevin Grogan

The Swiss major is close to its first submission for ‘pipeline in a pill’ iptacopan but has conceded defeat with branaplam as a potential treatment for Huntington’s disease.

Novartis HQ
• Source: Novartis

Novartis AG's pipeline update during its fourth-quarter results presentations was a mixed bag, with the company's enthusiasm for iptacopan tempered by the disappointing news that it has terminated development of branaplam for Huntington’s disease.

Hopes were high a couple of years ago when Novartis announced that after working on branaplam for over five years...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Neurological

More from Therapy Areas

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

 
• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

Draig Is All Fired Up To Transform Neuropsychiatric Field

 
• By Kevin Grogan

Wales-based group launches with $140m series A.

Immuneering Could Partner Atebimetinib Or Go It Alone After Phase IIa Success

 
• By Alaric DeArment

CEO Ben Zeskind said all options are on the table after atebimetinib showed impressive results in pancreatic cancer.